Life Science Breakfast
"Personalized Medicine"
 

Tuesday, December 4th
 7:30 am - 9:30 am at Swissnex

730 Montgomery Street - San Francisco
 

Registration

We are all witnessing a revolution in the understanding of health and disease, spurred on by the sequencing of the human genome and the subsequent creation of a map of human genetic variation. And, like most historic movements, this revolution has been given a name: personalized medicine. What does it mean to all of us? ; Four great companies playing in that field, from diagnostics to banking, will bring you exciting perspectives and answer all your questions about the New Trends in Personalized Medicine.

Breakfast will be served

Swissnex connects the dots in science, education, art and innovation,
between Switzerland and Western North America

Speakers:

Philippe J. Goix, Ph.D., President and Chief Executive Officer, Singulex, Inc.

Michael P McKenna, Chief Scientific Officer, Tethys

William J. Welch, Senior Vice President and Chief Commercial Officer, Monogram

Zachary R. Scott, Director, Burrill

________________________________________

Philippe J. Goix, Ph.D. President & Chief Executive Officer, Singulex, Inc.

Philippe Goix, Ph.D., has more than a decade of entrepreneurial biotechnology experience successfully leading fast growing, product-centered, innovative companies backed by institutional venture capitalists. Since joining Singulex in September 2004, Dr. Goix has driven system technology toward commercialization, secured strategic Intellectual Property for its technology, raised several “up rounds” of funding, and built a strategic reagent and diagnostics strategy.

Prior to joining Singulex, Philippe Goix was the founder of Guava Technologies, Inc., where he held successive positions as President and CTO.  Prior to this seven-year experience, Dr. Goix worked for more than 15 years in the field of laser analytical devices applied to fluid mechanics. He worked at CNRS in France, as a charge de recherche at Sandia National Laboratories, and at Stanford University as a scientist, where he developed sophisticated laser-based diagnostic tools to investigate complex fluidics systems. Dr. Goix holds a doctorate in physics from University of Rouen, France and an MBA from the University of San Francisco

.

Michael P McKenna, Chief Scientific Officer, Tethys
Dr. McKenna has made a career of managing advanced technology development and scaling technologies focused on product development. In his positions as Vice President of Operations and Collaborative Research at CuraGen Corporation, he led the development and industrialization of more than 15 processes spanning genomics, sequencing, and proteomics. This work yielded breakthrough publications in the whole genome protein interaction maps, whole genome sequencing technologies, and, in collaboration with Bayer Pharmaceuticals, the first generation on in vitro predictive toxicology assays. Dr. McKenna received his Ph.D. from Yale University and B.S. from Carnegie-Mellon University

Dr. Scott joined Burrill & Company in July of 2005 and is involved with sourcing and evaluating new investment opportunities across the life science spectrum. Prior to joining Burrill & Company, Dr. Scott was a General Surgery resident at Oregon Health Science University in Portland, Oregon. Dr. Scott has a BA in Economics from Duke University, an MD from the University of Texas Health Science Center at San Antonio, and an MBA and a certificate in Health Sector Management from the Fuqua School of Business at Duke University, where he was Fuqua Scholar. Dr. Scott is a member of the Alpha Omega Alpha Medical Honor Society.

William J. Welch has served as Monogram's Senior Vice President and Chief Commercial Officer since September 2005. From 1998 to 1999 and from 2001 to August 2005, Mr. Welch was with LaJolla Pharmaceutical, Inc., most recently as Vice President, Sales & Marketing. From 1999 to 2001, Mr. Welch was Vice President of Global Marketing for Dade Behring MicroScan where he managed marketing and strategic development for a $150 million business. From 1993 to 1998, Mr. Welch held a number of management positions with Abbott Laboratories, including General Manager of the Ambulatory Infusion Systems Division. Mr. Welch holds a BS from the University of California at Berkeley and an MBA from Harvard University

________________________________________